+

WO2007030589A3 - Pharmaceutical dosage forms and compositions comprising lecoztan - Google Patents

Pharmaceutical dosage forms and compositions comprising lecoztan Download PDF

Info

Publication number
WO2007030589A3
WO2007030589A3 PCT/US2006/034813 US2006034813W WO2007030589A3 WO 2007030589 A3 WO2007030589 A3 WO 2007030589A3 US 2006034813 W US2006034813 W US 2006034813W WO 2007030589 A3 WO2007030589 A3 WO 2007030589A3
Authority
WO
WIPO (PCT)
Prior art keywords
lecoztan
compositions
dosage forms
pharmaceutical dosage
methods
Prior art date
Application number
PCT/US2006/034813
Other languages
French (fr)
Other versions
WO2007030589A2 (en
Inventor
Krishnendu Ghosh
Arwinder S Nagi
Xiaohong Pan
Melissa Lin
Leonid Linberg
Ping Cai
Eric N C Browne
Michel Bernatchez
Mark Lankau
Sangeeta Raje
Original Assignee
Wyeth Corp
Krishnendu Ghosh
Arwinder S Nagi
Xiaohong Pan
Melissa Lin
Leonid Linberg
Ping Cai
Eric N C Browne
Michel Bernatchez
Mark Lankau
Sangeeta Raje
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Krishnendu Ghosh, Arwinder S Nagi, Xiaohong Pan, Melissa Lin, Leonid Linberg, Ping Cai, Eric N C Browne, Michel Bernatchez, Mark Lankau, Sangeeta Raje filed Critical Wyeth Corp
Priority to CA002620491A priority Critical patent/CA2620491A1/en
Priority to EP06790193A priority patent/EP1928863A2/en
Priority to AU2006287543A priority patent/AU2006287543A1/en
Priority to JP2008530186A priority patent/JP2009507850A/en
Priority to BRPI0615771-8A priority patent/BRPI0615771A2/en
Publication of WO2007030589A2 publication Critical patent/WO2007030589A2/en
Publication of WO2007030589A3 publication Critical patent/WO2007030589A3/en
Priority to IL189827A priority patent/IL189827A0/en
Priority to NO20081100A priority patent/NO20081100L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to, for example, novel formulations and methods for the delivery of 4-cyano-N-{(2R)-2-[4-(2,3-dihydro-benzo[l ,4]dioxin-5-yl)-piperazin-l -yl]-propyl}-N- pyridin-2-yl-benzamide, pharmaceutically acceptable salts thereof, structurally related compounds and/or metabolites; as well as to use of these formulations and methods for treating disease.
PCT/US2006/034813 2005-09-09 2006-09-06 Pharmaceutical dosage forms and compositions comprising lecoztan WO2007030589A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002620491A CA2620491A1 (en) 2005-09-09 2006-09-06 Pharmaceutical dosage forms and compositions comprising lecoztan
EP06790193A EP1928863A2 (en) 2005-09-09 2006-09-06 Pharmaceutical dosage forms and compositions comprising lecoztan
AU2006287543A AU2006287543A1 (en) 2005-09-09 2006-09-06 Pharmaceutical dosage forms and compositions comprising lecoztan
JP2008530186A JP2009507850A (en) 2005-09-09 2006-09-06 Pharmaceutical dosage forms and compositions comprising lecozotan
BRPI0615771-8A BRPI0615771A2 (en) 2005-09-09 2006-09-06 a method comprising administering to a patient an oral dosage form; method for minimizing an adverse side effect associated with administering lecozotan to a patient; method for administering lecozotan to a patient; method of treating alzheimer's disease in a patient; use of lecozotan in the preparation of a medicament in oral dosage form; and use of lecozotan in the preparation of a medicament in oral dosage form to minimize an adverse side effect associated with administering lecozotan to a patient.
IL189827A IL189827A0 (en) 2005-09-09 2008-02-28 Pharmaceutical dosage forms and compositions comprising lecoztan
NO20081100A NO20081100L (en) 2005-09-09 2008-03-03 Pharmaceutical dosage forms and compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71541705P 2005-09-09 2005-09-09
US60/715,417 2005-09-09

Publications (2)

Publication Number Publication Date
WO2007030589A2 WO2007030589A2 (en) 2007-03-15
WO2007030589A3 true WO2007030589A3 (en) 2007-11-01

Family

ID=37836444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034813 WO2007030589A2 (en) 2005-09-09 2006-09-06 Pharmaceutical dosage forms and compositions comprising lecoztan

Country Status (17)

Country Link
EP (1) EP1928863A2 (en)
JP (1) JP2009507850A (en)
KR (1) KR20080043855A (en)
CN (1) CN101258146A (en)
AR (1) AR058033A1 (en)
AU (1) AU2006287543A1 (en)
BR (1) BRPI0615771A2 (en)
CA (1) CA2620491A1 (en)
CR (1) CR9800A (en)
EC (1) ECSP088236A (en)
GT (1) GT200600403A (en)
IL (1) IL189827A0 (en)
NO (1) NO20081100L (en)
PE (1) PE20070334A1 (en)
RU (1) RU2008108216A (en)
TW (1) TW200800198A (en)
WO (1) WO2007030589A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
EP1904066B1 (en) 2005-07-06 2018-05-23 Sunovion Pharmaceuticals Inc. COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS
WO2010132521A1 (en) * 2009-05-13 2010-11-18 Sepracor Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026214A1 (en) * 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
WO2005044222A2 (en) * 2003-10-30 2005-05-19 Cipla Limited Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
WO2005092307A2 (en) * 2004-03-19 2005-10-06 Wyeth Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
WO2006093853A1 (en) * 2005-03-01 2006-09-08 Wyeth Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026214A1 (en) * 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
WO2005044222A2 (en) * 2003-10-30 2005-05-19 Cipla Limited Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
WO2005092307A2 (en) * 2004-03-19 2005-10-06 Wyeth Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
WO2006093853A1 (en) * 2005-03-01 2006-09-08 Wyeth Crystalline and amorphous 4-cyano-n{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHILDERS W E ET AL: "Synthesis and Biological Evaluation of Benzodioxanylpiperazine Derivatives as Potent Serotonin 5-HT1A Antagonists: The Discovery of Lecozotan", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 48, no. 10, 16 April 2005 (2005-04-16), pages 3467 - 3470, XP002391411, ISSN: 0022-2623 *
CHILDERS W.E. ET. AL.: "Lecozotan Hydrochloride", DRUGS OF THE FUTURE, vol. 32, no. 5, 2007, pages 399 - 407, XP002448050 *
FORSTER E A ET AL: "A PHARMACOLOGICAL PROFILE OF THE SELECTIVE SILENT 5-HT1A RECEPTOR ANTAGONIST, WAY-100635", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 281, no. 1, 1995, pages 81 - 88, XP000604092, ISSN: 0014-2999 *
HADDJERI NASSER ET AL: "Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 9, no. 5, September 1999 (1999-09-01), pages 427 - 440, XP002448046, ISSN: 0924-977X *
PATAT ET AL: "PI-34", CLINICAL PHARMACOLOGY & THERAPEUTICS, MOSBY-YEAR BOOK, ST LOUIS, MO, US, vol. 79, no. 2, February 2006 (2006-02-01), pages P16, XP005361172, ISSN: 0009-9236 *
SCHECHTER L E ET AL: "Lecozotan (SRA-333): A selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 314, no. 3, September 2005 (2005-09-01), pages 1274 - 1289 URL, XP002448048, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
RU2008108216A (en) 2009-10-20
GT200600403A (en) 2007-09-19
PE20070334A1 (en) 2007-05-08
AR058033A1 (en) 2008-01-23
CN101258146A (en) 2008-09-03
CA2620491A1 (en) 2007-03-15
IL189827A0 (en) 2008-11-03
WO2007030589A2 (en) 2007-03-15
ECSP088236A (en) 2008-04-28
AU2006287543A1 (en) 2007-03-15
EP1928863A2 (en) 2008-06-11
CR9800A (en) 2008-04-28
NO20081100L (en) 2008-06-03
JP2009507850A (en) 2009-02-26
KR20080043855A (en) 2008-05-19
BRPI0615771A2 (en) 2011-05-24
TW200800198A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
SE0302760D0 (en) New compounds
MX2008001606A (en) Substituted piperazines as metabotropic glutamate receptor antagonists.
ECSP066866A (en) DOSAGE FORMS AND PHARMACEUTICAL COMPOSITIONS REFERENCE TO RELATED APPLICATIONS
WO2004103279A3 (en) 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
MX2008002061A (en) Thiazolyl piperidine derivatives.
BRPI0409611A (en) piperazine derivatives and their use for the treatment of neurological and psychiatric disorders
MXPA04001500A (en) Compounds effecting glucokinase.
TNSN07236A1 (en) Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related disorders
HRP20080297T3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
GB0112348D0 (en) Compounds
TNSN06150A1 (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
MXPA04002338A (en) Carbazole derivatives and their use as npy5 receptor antagonists.
WO2007011878A3 (en) Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
EA200601194A1 (en) NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR
WO2006077024A3 (en) 5-aminoindole derivatives
ATE372995T1 (en) BENZO(B)(1,4)DIOXEPINE DERIVATIVES
UA84896C2 (en) Hydronopol derivatives as agonists on human orl1 receptors
WO2007030589A3 (en) Pharmaceutical dosage forms and compositions comprising lecoztan
EA200801634A1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
MX2008001608A (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists.
WO2008004100A9 (en) Therapeutic compounds
UA83870C2 (en) Bicycl 3.1.1]heptane substituted benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
DE602006016420D1 (en) AMINO ALKYLAMIDOMETHYL SUBSTITUTED 2- (4-SULFONYLAMINO) -3-HYDROXY-3,4-DIHYDRO-2H-CROMEN-6-YL DERIVATIVES AND THEIR USE AS COLUMN CHANNEL BLOCKERS
WO2005065315A3 (en) Bone targeting compounds for delivering agents to the bone for interaction therewith

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680032860.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2620491

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006790193

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 189827

Country of ref document: IL

Ref document number: 2006287543

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 936/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 566433

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 08023493

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 12008500565

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/003295

Country of ref document: MX

Ref document number: 2008530186

Country of ref document: JP

Ref document number: CR2008-009800

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087007106

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006287543

Country of ref document: AU

Date of ref document: 20060906

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008108216

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0615771

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080307

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载